HOME >> MEDICINE >> NEWS
Initial chemotherapy treatment reduces relapses in MS patients

DENVER, CO Mitoxantrone, a chemical routinely used to fight breast cancer, leukemia and malignant lymphoma, has found a new disease to battle: Multiple Sclerosis. Used in an initial intensive course of chemotherapy (induction therapy), mitoxantrone dramatically decreases disease activity in MS patients for at least four years, according to a study presented at the Annual Meeting of the American Academy of Neurology.

Induction therapy, frequently used against cancers, is designed to wipe out abnormal cells and allow for the regrowth of normal cells. Mitoxantrone for the treatment of MS has recently been approved by the U.S. Food and Drug Administration. It has been used to treat MS in France for more than a decade. Researchers from CHU Pontchaillou of Rennes, France, have demonstrated that mitoxantrone induction therapy for relapsing-remitting MS patients has produced dramatic results in disease activity.

Over the past ten years, 100 worsening relapsing-remitting MS patients were given initial mitoxantrone induction therapy for six months, with mitoxantrone combined with methylprednisolone administered intravenously on a monthly schedule. The annual relapse rate decreased significantly from 3.20 during the 12 months preceding mitoxantrone onset to 0.30 during the first year following induction onset, corresponding to a reduction of nearly 90 percent that was maintained for more than five years. The percentage of relapse-free patients was 76 percent at one year of follow-up, and was maintained at 64 percent, 45 percent, and 43 percent at years two, three and four, respectively, with a median time to the first relapse of 2.8 years.

The clinical benefit and reduction of disease activity supports our belief that mitoxantrone, as administered in this study, may be an effective induction treatment before initiating other long-term disease modifying therapies for worsening relapsing-remitting MS patients, commented study author Emmanuelle Le Pa
'"/>

Contact: Cheryl Alementi
calementi@aan.com
651-695-2737
American Academy of Neurology
17-Apr-2002


Page: 1 2

Related medicine news :

1. Initial findings of first comprehensive study into ageing process published
2. Initial Avon/NCI breast cancer research grants awarded in Progress for Patients awards program
3. Initially recommended drug dosages often too high, study finds
4. Initial clinical study shows safety and bioactivity of cancer vaccine
5. Bevacizumab combined with chemotherapy prolongs survival for some patients with advanced lung cancer
6. Breakthrough in medical research: New chemotherapy gives hope to brain tumour patients
7. MRI better than current standard in assessing neoadjuvant chemotherapy for breast cancer
8. Older women can benefit from chemotherapy to treat breast cancer
9. Resistance to chemotherapy
10. New treatment rivals chemotherapy for lymphoma, U-M study finds
11. Adding radiation therapy to chemotherapy improves survival in patients with high-risk breast cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Initial chemotherapy treatment reduces relapses patients

(Date:7/31/2015)... New York, New York (PRWEB) , ... ... ... Nationally renowned trial attorney Jason T. Brown’s live lecture on pharmaceutical negligence ... from July 28th, 2015 was well received with a 94% approval rating ...
(Date:7/31/2015)... ... July 31, 2015 , ... As part of their company mission, ... support of animal welfare organizations is essential to the longevity of their business. ... the National Association of Professional Pet Sitters (NAPPS) annual Presents 4 Pets supply drive. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Transfinder, a software company ... Total sales were up 16 percent year-over-year for the first six months ended June ... said he expected Transfinder to beat last year’s record-revenue mark of $10.4 million. , ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... “HARMONY 2015”, one of the industry’s premier thought leadership symposiums, hosted by ... and 6. The event attracts over 250 “C”-level executives, administrators, directors of ...
(Date:7/31/2015)... ... 2015 , ... Mullin/Ashley Associates , a Mid-Atlantic branding, ... Awards national competition for a marketing communications campaign created for Atlantic General ... Coastal Maryland and Southern Delaware. , A Bronze Award was won for the ...
Breaking Medicine News(10 mins):Health News:Re-Broadcast of Nationally Renowned Trial Attorney Jason T. Brown's Lecture on Pharmaceutical Negligence Now Available 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 2Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 3Health News:Dallas-based Park Cities Pet Sitter Selects Non-Profit Animal Welfare Organization “Angie’s Friends” as this Year’s Recipient of their Presents 4 Pets Supply Drive. 4Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 2Health News:Harmony Healthcare International Announces Speaker Line-up for “HARMONY 2015” 3Health News:Mullin/Ashley Associates Wins in the 2015 Aster Awards National Competition for Excellence in Medical Marketing 2
(Date:7/30/2015)... , July 30, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ ... into non-exclusive Development Agreements with Dexcom, Inc. to ... pumps with the Dexcom G5 and G6 continuous ... next generation pump platform with Dexcom,s future CGM ...
(Date:7/30/2015)... special edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 ... highlighting the success of the prescription drug benefit, commonly referred to as Part D. ... and videos here: http://onphr.ma/1INp9qQ ... ... ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3
Cached News: